China Chemical & Pharmaceutical Co., Ltd.
TWSE:1701.TW
21.15 (TWD) • At close August 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8,574.72 | 8,456.512 | 7,948.998 | 8,181.056 | 7,969.7 | 7,580.236 | 6,244.807 | 5,781.413 | 5,627.644 | 5,297.426 | 5,173.846 | 4,947.571 | 5,024.675 | 4,555.141 | 4,353.831 |
| Cost of Revenue
| 5,535.722 | 5,368.631 | 5,084.206 | 5,212.253 | 4,993.267 | 4,715.066 | 4,322.21 | 4,092.405 | 4,015.274 | 3,674.62 | 3,607.232 | 3,352.16 | 3,420.064 | 2,950.212 | 2,864.822 |
| Gross Profit
| 3,038.998 | 3,087.881 | 2,864.792 | 2,968.803 | 2,976.433 | 2,865.17 | 1,922.597 | 1,689.008 | 1,612.37 | 1,622.806 | 1,566.614 | 1,595.411 | 1,604.611 | 1,604.929 | 1,489.009 |
| Gross Profit Ratio
| 0.354 | 0.365 | 0.36 | 0.363 | 0.373 | 0.378 | 0.308 | 0.292 | 0.287 | 0.306 | 0.303 | 0.322 | 0.319 | 0.352 | 0.342 |
| Reseach & Development Expenses
| 485.656 | 435.732 | 391.335 | 444.175 | 451.784 | 403.385 | 344.302 | 325.083 | 326.669 | 362.105 | 354.56 | 320.6 | 309.051 | 258.092 | 213.685 |
| General & Administrative Expenses
| 345.338 | 319.185 | 277.342 | 218.188 | 197.32 | 213.959 | 192.453 | 188.216 | 167.099 | 155.945 | 159.06 | 169.846 | 170.396 | 164.346 | 172.014 |
| Selling & Marketing Expenses
| 2,070.338 | 1,964.192 | 1,784.754 | 1,916.296 | 1,939.653 | 1,889.407 | 1,108.541 | 889.274 | 872.646 | 825.974 | 817.96 | 843.801 | 843.348 | 887.031 | 817.495 |
| SG&A
| 2,324.019 | 2,283.377 | 2,062.096 | 2,134.484 | 2,136.973 | 2,103.366 | 1,300.994 | 1,077.49 | 1,039.745 | 981.919 | 977.02 | 1,013.647 | 1,013.744 | 1,051.377 | 989.509 |
| Other Expenses
| 49.651 | 55.058 | 105.414 | 102.027 | 52.81 | 18.126 | 45.208 | 51.653 | 114.819 | 144.892 | 55.441 | 26.054 | -1.9 | 15.746 | 69.406 |
| Operating Expenses
| 2,809.675 | 2,719.109 | 2,453.431 | 2,578.659 | 2,588.757 | 2,506.751 | 1,645.296 | 1,402.573 | 1,366.414 | 1,344.024 | 1,331.58 | 1,334.247 | 1,322.795 | 1,309.469 | 1,203.194 |
| Operating Income
| 229.323 | 620.157 | 682.472 | 669.377 | 502.583 | 358.419 | 277.301 | 286.435 | 245.956 | 278.782 | 235.034 | 261.164 | 281.816 | 295.46 | 285.815 |
| Operating Income Ratio
| 0.027 | 0.073 | 0.086 | 0.082 | 0.063 | 0.047 | 0.044 | 0.05 | 0.044 | 0.053 | 0.045 | 0.053 | 0.056 | 0.065 | 0.066 |
| Total Other Income Expenses Net
| -6.185 | -31.457 | -23.232 | -11.737 | -57.029 | 92.069 | 88.762 | 100.969 | 204.373 | 154.092 | 91.549 | 131.079 | 68.599 | 158.483 | 152.306 |
| Income Before Tax
| 232.488 | 588.7 | 659.24 | 657.64 | 445.554 | 450.488 | 366.063 | 387.404 | 450.329 | 432.874 | 326.583 | 389.659 | 350.415 | 453.943 | 438.121 |
| Income Before Tax Ratio
| 0.027 | 0.07 | 0.083 | 0.08 | 0.056 | 0.059 | 0.059 | 0.067 | 0.08 | 0.082 | 0.063 | 0.079 | 0.07 | 0.1 | 0.101 |
| Income Tax Expense
| 67.644 | 109.402 | 142.885 | 98.14 | 60.732 | 83.541 | 59.569 | 71.51 | 90.378 | 82.281 | 85.031 | 66.894 | 42.524 | 92.677 | 39.704 |
| Net Income
| 322.294 | 477.541 | 517.508 | 557.365 | 384.69 | 369.87 | 310.739 | 313.209 | 353.696 | 347.723 | 240.347 | 322.118 | 305.904 | 358.416 | 387.913 |
| Net Income Ratio
| 0.038 | 0.056 | 0.065 | 0.068 | 0.048 | 0.049 | 0.05 | 0.054 | 0.063 | 0.066 | 0.046 | 0.065 | 0.061 | 0.079 | 0.089 |
| EPS
| 1.08 | 1.61 | 1.74 | 1.88 | 1.29 | 1.24 | 1.05 | 1.05 | 1.19 | 1.17 | 0.81 | 1.09 | 1.03 | 1.21 | 1.3 |
| EPS Diluted
| 1.08 | 1.59 | 1.72 | 1.86 | 1.29 | 1.24 | 1.05 | 1.05 | 1.19 | 1.17 | 0.81 | 1.09 | 1.03 | 1.21 | 1.3 |
| EBITDA
| 543.586 | 922.401 | 972.466 | 965.642 | 747.049 | 744.026 | 656.454 | 676.376 | 737.57 | 696.042 | 561.512 | 593.938 | 529.051 | 614.691 | 600.394 |
| EBITDA Ratio
| 0.063 | 0.108 | 0.121 | 0.114 | 0.095 | 0.101 | 0.105 | 0.117 | 0.131 | 0.131 | 0.109 | 0.118 | 0.105 | 0.131 | 0.142 |